Menu Back toThe-Promise-and-Reality-of-Clinical-Trial-Transparency-Initiatives


The Promise and Reality of Clinical Trial Transparency Initiatives

Session Chair(s)

Thomas  Wicks, MBA

Thomas Wicks, MBA

  • Chief Strategy Officer
  • Trialscope, Inc., United States
The past decade has seen a virtual explosion of trial disclosure requirements and expectations around the world. This panel discussion will discuss the successes, challenges, and opportunities for improvement, looking back over the past ten years and forward to the expected developments in the next five.


Karla  Childers, MS

Panel Discussion

Karla Childers, MS

  • Bioethics & Strategic Projects Leader, Office of the Chief Medical Officer
  • Johnson & Johnson, United States
Deborah  Collyar

Panel Discussion

Deborah Collyar

  • President
  • Patient Advocates In Research (PAIR), United States
Joao  Ferreira, PharmD

Panel Discussion

Joao Ferreira, PharmD

  • Clinical Data Publication Manager
  • European Medicines Agency, Netherlands
Sini  Eskola, MPharm, MS, MSc

Panel Discussion

Sini Eskola, MPharm, MS, MSc

  • Director Regulatory Affairs
  • European Federation of Pharmaceutical Industries and Associations (EFPIA), Belgium
Deborah  Lincow

Panel Discussion

Deborah Lincow

  • Associate
  • Bioethics International, United States